Journal of the American Society of Hypertension
Volume 3, Issue 1 , Pages 19-24.e2, January 2009

Prevalence, awareness, and control of arterial hypertension in Denmark

  • Christel N. Kronborg, MD, PhD
  • ,
  • Jesper Hallas, MD, DMSc
  • ,
  • Ib A. Jacobsen, MD, DMSc

      Affiliations

    • Corresponding Author InformationCorresponding author: Ib A. Jacobsen, MD, DMSc, Department of Endocrinology M, Odense University Hospital, DK-5000 Odense, Denmark. Tel: +45 2720313; fax: +45 65919653

Department of Internal Medicine C, Odense University Hospital, Odense, Denmark

Received 12 May 2008; accepted 1 August 2008. published online 27 October 2008.

Abstract 

Hypertension is an important modifiable risk factor for cardiovascular disease. Risk is reduced by reduction of blood pressure (BP). The present survey estimated the prevalence of hypertension, awareness, treatment, and BP control in Denmark. BP was measured three times on one occasion in a representative sample (n = 7,767) of the Danish population ages 20 to 89 years. Persons with screening BP ≥140/90 mm Hg also measured BP at home. Participants with home BP ≥135/85 mm Hg in general and ≥125/75 mm Hg for patients with diabetes or renal disease were categorized as hypertensive together with those already on antihypertensive treatment. Awareness was registered by questionnaire. Treated patients with BP below relevant limits were categorized as controlled. Age-adjusted prevalence of hypertension was on the basis of screening BP 25.7% and by home BP 22.3%. Seventy-two percent of patients found hypertensive by home BP were aware of it, 64% were treated, and 57% of those treated were controlled by office BP and 68% by home BP. One-fifth of the adult Danish population was found to be hypertensive, Awareness and control of hypertension was better than in most previous reports. Control rates similar to those of clinical trials are achievable in clinical practice.

Keywords: Epidemiology, antihypertensive therapy, detection, blood pressure

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This study was funded by Apotekerfonden of 1991, The Danish Heart Foundation, The University of Southern Denmark, the County of Funen, and to a smaller extent by Pfizer, Novartis, Boehringer-Ingelheim, Solvay, and Sanofi-Synthelabo. Dr. Hallas has received research Grants from Novartis, Nycomed, and Merck Sharp & Dohme, and fees for teaching from Astra-Zeneca, Nycomed, Pfizer, and the Danish Association of Pharmaceutical Industry.

 Supplemental Material is available at www.ashjournal.com.

PII: S1933-1711(08)00148-4

doi:10.1016/j.jash.2008.08.001

Journal of the American Society of Hypertension
Volume 3, Issue 1 , Pages 19-24.e2, January 2009